<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336777">
  <stage>Registered</stage>
  <submitdate>8/04/2011</submitdate>
  <approvaldate>18/04/2011</approvaldate>
  <actrnumber>ACTRN12611000402943</actrnumber>
  <trial_identification>
    <studytitle>Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates, and the incidence of fractures</studytitle>
    <scientifictitle>Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates in Older Adults, and the incidence of non-vertebral fractures.</scientifictitle>
    <utrn>U1111-1120-6224</utrn>
    <trialacronym>ViDA (Vitamin D Assessment) Trial</trialacronym>
    <secondaryid>HRC 10/400</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular Disease</healthcondition>
    <healthcondition>Respiratory Disease</healthcondition>
    <healthcondition>Non-vertebral fractures</healthcondition>
    <healthcondition>Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Vitamin D3 (cholecalciferol) 200,000 IU oral capsule at baseline, then 100,000 IU oral capsule monthly for 4 years </interventions>
    <comparator>Placebo capsule with sunflower lecithin</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of fatal and non-fatal cardiovascular disease, as assessed by mortality, hospital discharges and family doctors.</outcome>
      <timepoint>4 years and 6 months after randomisation of first participant.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence rate of respiratory disease, as assessed by mortality, hospital discharges and consultations with family doctors.</outcome>
      <timepoint>4 years and 6 months after randomisation of first participant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence rate of non-vertebral fractures, as assessed by hospital discharges, consultations with family doctors and self-reported questionnaires.</outcome>
      <timepoint>4 years and 6 months after randomisation of first participant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first cancer for all neoplasms: ICD-10 codes: C00-D09 (excluding non-melanoma skin cancer) reported after randomization to the NZ Cancer Registry </outcome>
      <timepoint>From randomization to stopping the study medication (31 July 2015)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	age 50-84 years;
2.	ability to give informed consent;
3.	resident in Auckland at recruitment;
4.	anticipated residence in New Zealand for the 4-year study period.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>84</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.	current use of vitamin D supplements (&gt;600 IU per day if aged 50-70 years; &gt;800 IU per day if aged 71-84 years);
2.	diagnosis of psychiatric disorders that would limit ability to comply with study protocol - ie. history of regular exacerbation of major psychosis (schizophrenia, bipolar disorder) in last 2 years 
3.	history of hypercalcaemia, nephrolithiasis, sarcoidosis, parathyroid disease or gastric bypass surgery;
4.	enrolled in another study which could affect participation in the vitamin D study;
5.	serum calcium from baseline blood sample &gt;2.50 mmol/L.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be recruited from patient registers of general practitioners in Auckland.

Once eligibility is confirmed, randomisation to either arm of the study will be done by computer.</concealment>
    <sequence>Randomisation with variable block size within 5 year age and ethnic strata.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/04/2011</anticipatedstartdate>
    <actualstartdate>3/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>23/01/2013</actualenddate>
    <samplesize>5110</samplesize>
    <actualsamplesize>5108</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/07/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>School of Population Health,
Tamaki Campus,
University of Auckland,
Private Bag 92019,
Auckland, 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Level 3 - ProCare Building, 
110 Stanley Street, 
Auckland, 1010.</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Accident Compensation Commission</fundingname>
      <fundingaddress>80-83 Molesworth St.,
Wellington, 6140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Carlos A. Camargo, Jr, MD DrPH (Co-PI)</sponsorname>
      <sponsoraddress>Massachusetts General Hospital
326 Cambridge St, Suite 410
Boston
Massachusetts 02114</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main aims of the study are to see if vitamin D supplementation reduces the incidence rates of cardiovascular disease, respiratory disease and non-vertebral fractures.</summary>
    <trialwebsite />
    <publication>Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. JAMA Cardiol. 2017;2(6):608-616.

Khaw KT, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. The Lancet. Diabetes &amp; Endocrinology. 2017;5(6):438-447</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi Region Ethics Committee</ethicname>
      <ethicaddress>c/- Ministry of Health
1-3 The Terrace
Level 1
Wellington 6011</ethicaddress>
      <ethicapprovaldate>21/10/2010</ethicapprovaldate>
      <hrec>MEC/09/08/082</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Robert Scragg</name>
      <address>School of Population Health, 
University of Auckland, Tamaki Campus, 
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand.</address>
      <phone>+64-9-3737 599, ext 86336</phone>
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Robert Scragg</name>
      <address>School of Population Health, 
University of Auckland, Tamaki Campus, 
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand </address>
      <phone>+64-9-3737 599, ext 86336</phone>
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robert Scragg</name>
      <address>School of Population Health, 
University of Auckland, Tamaki Campus, 
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand</address>
      <phone />
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Robert Scragg</name>
      <address>School of Population Health, 
University of Auckland, Tamaki Campus, 
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand</address>
      <phone>+64-9-9236336</phone>
      <fax />
      <email>r.scragg@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>